甲状腺癌血浆循环DNA中SOX17基因甲基化与患者病情及预后的关系  

Methylation of SOX17 Gene in Plasma Circulating DNA and Its Correlation with Disease Status and Prognosis in Patients with Papillary Thyroid Carcinoma

作　　者：晁祥嵩 孙佳斌 赵长海[1] CHAO Xiangsong;SUN Jiabin;HOU Yinglong(Jiamusi Central Hospital,Heilongjiang Jiamusi 154002,China)

机构地区：[1]黑龙江省佳木斯市中心医院乳腺甲状腺外科,黑龙江佳木斯154002

出　　处：《河北医学》2024年第10期1695-1700,共6页Hebei Medicine

基　　金：黑龙江省卫生健康委科研课题,(编号:2019-352)。

摘　　要：目的:探讨乳头状甲状腺癌(PTC)血浆循环DNA中Y染色体相关高迁移率族盒17(SOX17)基因甲基化与患者病情及预后的关系。方法:收集2022年6月至2023年12月在本院接受手术切除的152例PTC患者的甲状腺癌样本和术前血液标本。通过甲基化特异性PCR(MSP)检测PTC组织和血浆循环DNA中SOX17启动子甲基化。结果:MSP检测结果显示,152例PTC组织中有71例SOX17甲基化(46.7%),血浆循环DNA中有76例SOX17甲基化(50.0%)。Spearman相关分析结果显示,血浆循环DNA中SOX17甲基化与PTC组织中SOX17甲基化显著相关(r=0.382,P<0.001)。在PTC组织和血浆循环DNA中,SOX17甲基化与肿瘤分期Ⅱ~Ⅲ期、肿瘤大小≥2cm、LNM例数显著相关(P<0.05)。此外,血浆循环DNA中SOX17甲基化与ETE发生显著相关(P<0.05)。血浆循环DNA中SOX17甲基化(OR=9.564、2.744,95%CI=3.875~23.602、1.109~6.792)是PTC患者发生淋巴结转移(LNM)、甲状腺外侵犯(ETE)的独立影响因素(P<0.05)。血浆循环DNA中SOX17甲基化在预测LNM和ETE的能力较高,曲线下面积(AUC)为0.731、0.630(灵敏度为74.0%、65.6%,特异度为72.2%、60.4%);PTC组织SOX17甲基化预测LNM和ETE的能力较低,曲线下面积(AUC)为0.604、0.562(灵敏度为57.5%、54.1%,特异度为63.3%、58.2%)。结论:在PTC发生、发展过程中,肿瘤组织及血浆DNA中SOX17基因启动子甲基化具有高度一致性,并且血浆DNA中SOX17基因启动子甲基化预测LNM和ETE的能力较高。Objective:To explore the relationship between SOX17 gene methylation in plasma circulating DNA and the disease condition and prognosis of patients with papillary thyroid carcinoma(PTC).Methods:Thyroid cancer tissue and preoperative blood samples were collected from 152 PTC patients who underwent surgical resection between June 2022 and December 2023.Methylation-specific PCR(MSP)was used to detect SOX17 promoter methylation in PTC tissues and plasma circulating DNA.Results:MSP results showed that 71 out of 152 PTC tissue samples(46.7%)and 76 plasma circulating DNA samples(50.0%)exhibited SOX17 methylation.Spearman correlation analysis indicated a significant correlation between SOX17 methylation in plasma circulating DNA and PTC tissues(r=0.382,P<0.001).SOX17 methylation in PTC tissue and plasma circulating DNA was significantly associated with tumor stagesⅡ~Ⅲ,tumor size≥2cm,and lymph node metastasis(LNM)(P<0.05).Furthermore,SOX17 methylation in plasma circulating DNA was significantly related to the occurrence of extrathyroidal extension(ETE)(P<0.05).SOX17 methylation in plasma circulating DNA was identified as an independent factor influencing LNM and ETE in PTC patients(OR=9.564,2.744;95%CI=3.875~23.602,1.109~6.792,P<0.05).The predictive ability of SOX17 methylation in plasma circulating DNA for LNM and ETE was relatively high,with an area under the curve(AUC)of 0.731 and 0.630(sensitivity 74.0%,65.6%;specificity 72.2%,60.4%).In contrast,the predictive ability of SOX17 methylation in PTC tissues for LNM and ETE was lower,with an AUC of 0.604 and 0.562(sensitivity 57.5%,54.1%;specificity 63.3%,58.2%).Conclusion:SOX17 promoter methylation in tumor tissue and plasma DNA exhibits high consistency during the occurrence and progression of PTC.Moreover,SOX17 promoter methylation in plasma DNA has a higher predictive value for LNM and ETE.

关 键 词：乳头状甲状腺癌 Y染色体相关高迁移率族盒17 血浆 甲基化特异性PCR 

分 类 号：R736.1[医药卫生—肿瘤]